Abstract: Scars are a common dermatological condition, typically characterized by the formation of fibrous tissue (scar tissue) during the healing process following skin trauma. Keloids are defined as abnormally proliferative scar tissue that extends above the skin′s surface, resulting in altered skin texture and an irregular appearance, often resembling nodules. Most keloids arise from surgical interventions, localized folliculitis, or acne. They can sometimes be extremely painful, significantly impacting both physical and mental health, as well as overall quality of life. Keloids treated with conventional methods frequently exhibit recurrent hypertrophic growth, posing considerable challenges for clinical management. Radionuclide application therapy is a first-line treatment for preventing the recurrence of scars after surgery. This therapy has been utilized in China for over half a century, with clinical practice demonstrating a high safety profile. Isotopes such as ³²P or ⁹⁰Sr emit β-rays, which have a short penetration depth and strong ionizing ability in tissues, thereby preventing damage to the dermis and posing no systemic risks . Treatment with ³²P or ⁹⁰Sr application is straightforward, safe, painless, and highly effective, and has gained significant attention in clinical practice recently. This consensus aims to provide guidelines for treating keloids with radionuclide application therapy, with the goals of optimizing treatment protocols, enhancing therapeutic outcomes, and minimizing adverse effects.